Led · Equity · Feb 2022

Bioniq builds AI-driven personalised supplements that are formulated from users' blood test results. The company, launched in 2019 in London, ships globally across five continents and offers products in 70 countries. It has created unique formulas for over 300,000 users and says its total user base will grow more than tenfold by the end of 2024. Bioniq has launched a hyper-personalised product called Build Your Own to allow more precise, goal-based nutrient routines. The company partners with health and sports institutions such as Lanserhof and the UFC, and counts elite athletes — including Soccer World Cup champions and NBA All‑Stars — among its users. Leadership emphasizes measurable before-and-after nutrient snapshots and proven optimisation as core assets for growth and credibility. Bioniq creates 100% customized daily supplements using advanced blood biomarker analysis combined with self-reported health data and a patent-pending AI algorithm. Each user receives a unique formula of up to 120 ingredients delivered in patented prebiotic guar granules designed for improved bioavailability and micro-dosing. Products are Swiss-made, pharmaceutical-grade, and the company offers daily nutrient support, 1:1 nutrition consultations, and educational resources. Bioniq reports sales in 70+ countries and a user base that grew more than fivefold this year, with the U.S. now contributing over 60% of global sales. The company highlights partnerships with leading health and sports institutions such as Lanserhof and the UFC and is used by elite athletes across sports. Management says it will accelerate global expansion with particular focus on the U.S., Europe, and the Middle East, and Cristiano Ronaldo will participate in future brand and product innovation. Bioniq builds AI-driven, patent-pending algorithms that generate personalized supplement formulas from blood biomarker data and individual inputs such as height, weight, age, lifestyle and health goals. The company offers Bioniq PRO, which integrates blood test data (including partner lab testing and 1:1 nutrition consultations), and Bioniq GO, a questionnaire-based, more accessible option. All supplements are Swiss-made, pharmaceutical-grade, micro-dosed and delivered in patented prebiotic guar granules to maximize bioavailability. Bioniq has compiled the largest proprietary biochemical database of its kind with blood test data from customers across five continents and has created unique formulas for over 100,000 users. The U.S. now represents over 50% of its customer base, with some regions growing more than 500% in the last two quarters, and the company partners with institutions such as Lanserhof and the UFC and serves elite athletes. It plans to use new funding to expand global laboratory integrations, accelerate product development, grow market, operational and HR presence in the U.S. and Middle East, and implement a corporate platform for medical, wellness, and athletic institutions. bioniq develops hyper-personalized supplement products, most recently launching bioniq GO, a subscription product priced at £49/month. GO leverages 3 million proprietary biochemical data points drawn from more than 50,000 blood tests across over 30,000 clients and 25 medical publications. The company says its GO formulas can include up to 34 components with as many as 10 million possible combinations and claims personalization 200,000 times higher than similar products. Founders include CEO Vadim Fedotov (a former German national team basketball player) and Dr. Konstantin Karuzin, a neurosurgeon who previously developed performance-improvement systems for professional athletes. Earlier this year bioniq acquired LOEWI, a scientific spin-off of TU München that provides tailor-made nutrients based on blood work and lifestyle. The company positions itself around data aggregation and digital health monitoring to improve personalization over time as it ingests new blood samples.